BiotechTube
Cepheid

Cepheid

Sunnyvale, United States· Est.
cepheid.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $267.4M

Overview

Cepheid is a leader in molecular diagnostics, renowned for its fully integrated, automated GeneXpert system that delivers rapid, cartridge-based PCR test results. The company offers a broad menu of FDA-cleared and CE-marked tests across critical areas including respiratory infections, healthcare-associated infections (HAIs), tuberculosis, virology, and oncology. As a subsidiary of Danaher Corporation, Cepheid leverages its scale and operational excellence to drive global adoption, particularly through programs like 'Global Access' which aims to make essential tests like TB diagnostics available and affordable in low-resource settings.

Infectious DiseaseRespiratoryOncologyWomen's HealthSexual HealthTuberculosis

Technology Platform

GeneXpert system: fully integrated, automated, cartridge-based platform for real-time PCR (polymerase chain reaction) testing. It performs sample preparation, nucleic acid extraction, amplification, and detection in a single, closed-system cartridge.

Funding History

4
Total raised:$267.4M
IPO$99.4M
Series C$85M
Series B$50M
Series A$33M

Opportunities

The growing demand for rapid, point-of-care molecular diagnostics for respiratory syndromes, antimicrobial stewardship, and hospital infection control presents a major expansion opportunity.
Furthermore, the global health focus on diseases like TB and HIV in low-resource settings, addressed through its Global Access program, builds a foundational presence in emerging markets.

Risk Factors

Intense competition from other molecular diagnostic companies, ongoing pricing pressure from healthcare systems, and regulatory hurdles for new test approvals are significant risks.
The company also faces potential supply chain disruptions and the long-term risk of technological disruption to its core PCR-based cartridge model.

Competitive Landscape

Cepheid competes in the rapid molecular diagnostics space with companies like BioFire Diagnostics (bioMérieux), Abbott (ID NOW, Alinity m), Roche (cobas Liat), LumiraDx, and Qiagen (QIAstat-Dx). Competition is based on test menu breadth, turnaround time, ease of use, instrument footprint, connectivity, and cost-per-test.

More companies in Diagnostics & Precision Medicine →More companies in United States →